fda compounding semaglutide warning letters october 2025 The sent a letter to the maker of Ozempic and Wegovy over unreported potential GLP-1 side effects. Here's what to know Demand for Unapproved Weight-Loss Drug

semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials

Obsessive-compulsive disorder (OCD): An RCT in 48 patients found that NAC (2,400 mg/day) as an add-on to fluvoxamine significantly improved Yale-Brown OCD Scale scores compared to placebo over 12 weeks (Afshar et al., J Clin Psychopharmacol, 2012) [72]

But the next wave of therapies in development is focused on ease of administration, including oral options and less-frequent dosing

Slow, personalized dose titration through a compounding pharmacy can help minimize them

It is moving toward becoming a tightly controlled, high-value pharmaceutical product

Lipo C injections, also called lipotropic injections, are designed to aid weight loss by promoting fat metabolism and increasing energy